Knight Therapeutics Inc. to Begin Trading on March 3, 2014

NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: Knight Therapeutics Inc. 
TSX VENTURE SYMBOL:  GUD 
FEBRUARY 28, 2014 
Knight Therapeutics Inc. to Begin Trading on March 3, 2014 
MONTREAL, CANADA--(Marketwired - Feb. 28, 2014) - The Common Shares of Knight
Therapeutics Inc. (TSX VENTURE:GUD) are now listed on the TSX Venture Exchange
under the ticker symbol GUD and are expected to begin trading on March 3, 2014
at opening. Knight Therapeutics Inc. ("Knight") is owned by the
former shareholders of Paladin Labs Inc. ("Paladin") pursuant to a
spin-off transaction that was effected today, along with the acquisition of
Paladin by Endo Health Solutions Inc. (NASDAQ:ENDP), a leading U.S.-based
specialty pharmaceutical company. 
Jonathan Ross Goodman, the co-founder and former CEO of Paladin since inception
is Knight's CEO. Knight's board of directors is composed of Mr.
Goodman and 4 other independent directors 3 of whom are former Paladin Board
members. 
Pursuant to the spin-off transaction, Knight has 3 main assets: (1) a royalty
stream from sales of Impavido(R) outside of the United States. Impavido is
approved for sale in 14 countries for the treatment of Leishmaniasis and has
been licensed by Knight to Paladin. Applying this royalty stream to Impavido
sales in 2012, $463,990 in royalties would have been generated by Knight. (2) A
U.S. FDA submission for Impavido, which, if approved, would result in the
issuance to Knight of a Priority Review Voucher, discussed further below and
(3) $1 million in cash. 
"I led Paladin from birth 18 years ago to sale to Endo today." said
Mr. Goodman. "During this time," he continued "Paladin
experienced 18 consecutive years of record revenues. This resulted in
Paladin's share price increasing over 100 times from $1.50 per share to
$150. Knight won't rest until it is at least as successful." 
Conference Call  
Knight will conduct a conference call with financial analysts to discuss this
news release on March 3, 2014 at 8:00 a.m. Investors and other interested
parties may call 877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922
(local or international). 
About Knight Therapeutics Inc.:  
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian and world markets. Knight
Therapeutics' shares will trade on the TSX-V under the symbol GUD. For
more information about Knight Therapeutics, please visit the Company's web
site at www.gud-knight.com or at www.sedar.com. 
Priority Review Voucher  
Developed by the U.S. FDA in 2007, a Priority Review Voucher ("PRV")
is an incentive for companies to invest in new drugs and vaccines for neglected
tropical diseases. A Priority Review means that the time it takes the FDA to
review a new drug application is reduced. The PRV is transferable and can be
sold and entitles the bearer to a priority review for any product. To date,
only 3 companies have received a PRV and none have been sold. 
This press release may contain forward-looking statements and predictions.
These forward-looking statements, by their nature, necessarily involve risks
and uncertainties that could cause actual results to differ materially from
those contemplated by the forward-looking statements. The Company considers the
assumptions on which these forward-looking statements are based to be
reasonable at the time they were prepared, but cautions that these assumptions
regarding the future events, many of which are beyond the control of the
Company and its subsidiaries, may ultimately prove to be incorrect. Factors and
risks, which could cause actual results to differ materially from current
expectations, are discussed in the Company's final application for listing
on the TSX Venture and can be found on SEDAR at www.sedar.com, which investors
should consult for additional information. The Company disclaims any intention
or obligation to update or revise any forward-looking statements whether as a
result of new information or future events and except as required by law.  
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
Jonathan Ross Goodman
514-484-4483 
INDUSTRY:  Pharmaceuticals and Biotech - Drugs 
SUBJECT:  TRD 
-0-
-0- Feb/28/2014 14:07 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.